Prof Arun Azad
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
527 Scholarly works
11 Projects
HIGHLIGHTS
2026
Journal article
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma
DOI: 10.1038/s41467-026-74255-x2026
Journal article
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer
DOI: 10.1111/bju.702832026
Journal article
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
DOI: 10.1016/S0140-6736(26)01089-52026
Journal article
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies
DOI: 10.2967/jnumed.126.2720852023
Research grants (ARC, NHMRC, MRFF)
Optimising Radiopharmaceutical Therapy to Improve Clinical Outcomes in Advanced Prostate Cancer
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
Vca Clinical Research Fellowship
RECENT SCHOLARLY WORKS
2026
Journal article
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
DOI: 10.1007/s10928-026-10038-72026
Journal article
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer
DOI: 10.1056/NEJMoa26041262026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842026
Journal article
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
DOI: 10.1016/j.eururo.2026.03.0242026
Journal article
Clonal Hematopoiesis after177 Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617
DOI: 10.1016/j.eururo.2025.08.015
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Understanding Biomarkers of Response and Resistance to 177-Lutetium-Psma (LuPSMA) in Metastatic Castrate-Resistant Prostate Cancer
2027
Research grants (other domestic)
PETomics for Precision Theranostics: Multimodal Deep Learning to Personalise Treatment Selection in Metastatic Prostate Cancer